Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: Studies in unselected patients and monozygotic disease- discordant twins

Arthritis and Rheumatism

Volumn 39, Issue 11, 1996, Pages 1840-1851

  Stohl, William ^a,b   Elliott, Julie E ^a   Hamilton, Ann S ^a   Deapen, Dennis M ^a   Mack, Thomas M ^a   Horwitz, David A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3;

ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DAUDI CELL; DISEASE ACTIVITY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; MONOZYGOTIC TWINS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ADULT; ANTIGENS, CD3; ANTIGENS, CD56; DISEASES IN TWINS; FEMALE; HUMANS; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; T-LYMPHOCYTES; TWINS, MONOZYGOTIC;

EID: 0029910218     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780391110     Document Type: Article

References (73)

1. Takeuchi T, Abe T, Koide J, Hosono O, Morimoto C, Homma M: Cellular mechanism of DNA-specific antibody synthesis by lymphocytes from systemic lupus erythematosus patients. Arthritis Rheum 27:766-773, 1984
2. + T helper cells in humans augment the production of pathogenic anti-DNA auto-antibodies associated with lupus nephritis. J Immunol 143:103-112, 1989
3. Linker-Israeli M, Quismorio FP Jr, Horwitz DA: CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 33:1216-1225, 1990
4. - T helper cell lines that express the γδ T-cell antigen receptor. Proc Natl Acad Sci U S A 87:7020-7024, 1990
5. Horwitz DA. Stohl W: T lymphocytes, cytokines, and immune regulation in systemic lupus erythematosus. In, Dubois' Lupus Erythematosus. Fourth edition. Edited by DJ Wallace, BH Hahn, Philadelphia, Lea and Febiger, 1993
6. Morimoto C, Reinherz EL, Schlossman SF, Schur PH, Mills JA, Steinberg AD: Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest 66:1171-1174, 1980
7. Bakke AC, Kirkland PA, Kitridou RC, Quismorio FP Jr, Rea T, Ehresmann GR. Horwitz DA: T lymphocyte subsets in systemic lupus erythematosus: correlations with corticosteroid therapy and disease activity. Arthritis Rheum 26:745-750, 1983
8. Volk H-D, Kopp J, Körner IJ, Jahn S, Grunow R, Barthelmes H, Fiebig H: Correlation between the phenotype and the functional capacity of activated T cells in patients with active systemic lupus erythematosus. Scand J Immunol 24:109-114, 1986
9. Rosenthal CJ, Franklin EC: Depression of cellular-mediated immunity in systemic lupus erythematosus: relation to disease activity. Arthritis Rheum 18:207-217, 1975
10. Bermas BL, Petri M, Goldman D, Mittleman B. Miller MW, Stocks NI, Via CS, Shearer GM: T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol 14:169-177, 1994
11. Abdou NI, Sagawa A, Pascual E, Hebert J, Sadeghee S: Suppressor T-cell abnormality in idiopathic systemic lupus erythematosus. Clin Immunol Immunopathol 6:192-199, 1976
12. Bresnihan B, Jasin HE: Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus. J Clin Invest 59:106-116, 1977
13. Sakane T, Steinberg AD, Green I: Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 75:3464-3468, 1978
14. Smith JB, DeHoratius RJ: Deficient autologous mixed lymphocyte reactions correlate with disease activity in systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol 48:155-162, 1982
15. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M: Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665-1673, 1990
16. Stohl W: Impaired polyclonal T cell cytolytic activity: a possible risk factor for systemic lupus erythematosus. Arthritis Rheum 38:506-516, 1995
17. A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest 75:932-943, 1985
18. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH: The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136:4480-4486, 1986
19. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J: A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med 164:351-356, 1986
20. Goto M, Tanimoto K, Horiuchi Y: Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody. Arthritis Rheum 23:1274-1281, 1980
21. Hoffman T: Natural killer function in systemic lupus erythematosus. Arthritis Rheum 23:30-35, 1980
22. Oshimi K, Gonda N, Sumiya M, Kano S: Effects of corticosteroids on natural killer cell activity in systemic lupus erythematosus. Clin Exp Immunol 40:83-88, 1980
23. Silverman SL, Cathcart ES: Natural killing in systemic lupus erythematosus: inhibitory effects of serum. Clin Immunol Immunopathol 17:219-226, 1980
24. Karsh J, Dorval G, Osterland CK: Natural cytotoxicity in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 19:437-446, 1981
25. Katz P, Zaytoun AM, Lee JH, Panush RS, Longley S: Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event. J Immunol 129:1966-1971, 1982
26. + cells. Arthritis Rheum 26:623-629, 1983
27. Sibbitt WL Jr, Mathews PM, Bankhurst AD: Natural killer cell in systemic lupus erythematosus: defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest 71:1230-1239, 1983
28. Tsokos GC, Smith PL, Christian BC, Lipnick RN, Balow JE, Djeu JY: Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 34:379-386, 1985
29. Takeda K, Dennert G: The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation. B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 177:155-164, 1993
30. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982
31. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992
32. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM: A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35:311-318, 1992
33. Stohl W, Posnett DN, Chiorazzi N: Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies. J Immunol 138:1667-1673, 1987
34. Howard FD, Ledbetter JA, Wong J, Bieber CP, Stinson EB, Herzenberg LA: A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation. J Immunol 126:2117-2122, 1981
35. Kamoun M, Martin PJ, Hansen JA, Brown MA, Siadak AW, Nowinski RC: Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med 153: 207-212, 1981
36. Verbi W, Greaves MF, Schneider C, Koubek K, Janossy G, Stein H, Kung P, Goldstein G: Monoclonal antibodies OKT11 and OKT11A have pan-T reactivity and block sheep erythrocyte "receptors". Eur J Immunol 12:81-86, 1982
37. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J: Human natural killer cell adhesion molecules: differential expression after activation and participation in cytolysis. J Immunol 145:3194-3201, 1990
38. Stohl W, Tovar Z, Talal N: Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and-dependent components. J Immunol 144:3718-3725, 1990
39. Stohl W, Elliott JE, Linsley PS: Human T cell-dependent B cell differentiation induced by Staphylococcal superantigens. J Immunol 153:117-127, 1994
40. Stohl W: Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus. Clin Immunol Immunopathol 63: 163-172, 1992
41. Loughran TP Jr, Draves KE, Starkebaum G, Kidd P, Clark EA: Induction of NK activity in large granular lymphocyte leukemia: activation with anti-CD3 monoclonal antibody and interleukin 2. Blood 69:72-78, 1987
42. Andersen PM, Bach FH, Ochoa AC: Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Cancer Immunol Immunother 27:82-88, 1988
43. Stohl W, Elliott JE: Stimulation of human peripheral blood mononuclear cells with anti-CD3 monoclonal antibody vs IL2: disparate effects on T cell-dependent B cell differentiation despite similar effects on generation of unrestricted cytolytic activity. Clin Immunol Immunopathol 65:30-38, 1992
44. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687-1696, 1994
45. Leeuwenberg JFM, Spits H, Tax WJM, Capel PJA: Induction of nonspecific cytotoxicity by monoclonal anti-T3 antibodies. J Immunol 134:3770-3775, 1985
46. Spits H, Yssel H, Leeuwenberg J, de Vries JE: Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J Immunol 15:88-91, 1985
47. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530, 1994
48. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650-652, 1994
49. Walsh CM, Glass AA, Chiu V, Clark WR: The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J Immunol 153:2506-2514, 1994
50. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
51. Adachi M, Watanabe-Fukunaga R, Nagata S: Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A 90:1756-1760, 1993
52. Wu J, Zhou T, He J, Mountz JD: Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 178:461-468, 1993
53. Chu J-L, Drappa J, Parnassa A, Elkon KB: The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 178:723-730, 1993
54. Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davis-Smith T, Smith CA, Hunter K, Bhat D, Din W, Goodwin RG, Seldin MF: The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1:131-136, 1994
55. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976, 1994
56. Ramsdell F, Seaman MS, Miller RE, Tough TW, Alderson MR, Lynch DH: Gld/gld mice are unable to express a functional ligand for Fas. Eur J Immunol 24:928-933, 1994
57. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243-269, 1991
58. Wu J, Zhou T, Zhang J, He J, Gause WC, Mountz JD: Correction of accelerated autoimmune disease by early replacement of the mutated lpr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci U S A 91:2344-2348, 1994
59. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349, 1995
60. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935-946, 1995
61. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988
62. Nunez G, Seto M, Seremetis S, Ferrero D, Grignani F, Korsmeyer SJ, Dalla-Favera R: Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. Proc Natl Acad Sci U S A 86:4589-4593, 1989
63. Tsujimoto Y: Overexpression of the human BCL-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B cells. Proc Natl Acad Sci U S A 86:1958-1962, 1989
64. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, Harris AW: Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 88:8661-8665, 1991
65. Gatenby PA, Irvine M: The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J Autoimmun 7:623-631, 1994
66. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwazaki S: Expression and function of Fas antigen and bcl-2 in human systemic lupus erythematosus lymphocytes. Clin Immunol Immunopathol 73:109-114, 1994
67. Aringer M, Wintersberger W, Steiner CW, Kiener H, Presterl E, Jaeger U, Smolen JS, Graninger WB: High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 37:1423-1430, 1994
68. Harada M, Lin T, Kurosawa S, Maeda T, Umesue M, Itoh O, Matsuzaki G, Nomoto K: Natural killer cells inhibit the development of autoantibody production in (C57BL/6 X DBA/2)F1 hybrid mice injection with DBA/2 spleen cells. Cell Immunol 161:42-49, 1995
69. Alcocer-Varela J, Alarcon-Segovia D: Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 69:1388-1392, 1982
70. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA: Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 130:2651-2655, 1983
71. Miyasaka N, Nakamura T, Russell IJ, Talal N: Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 31:109-117, 1984
72. Sherris D, Stohl W, Mayer L: Characterization of lymphokines mediating B cell growth and differentiation from monoclonal anti-CD3 antibody-stimulated T cells. J Immunol 142:2343-2351, 1989
73. Kos FJ, Engleman EG: Requirement for natural killer cells in the induction of cytotoxic T cells. J Immunol 155:578-584, 1995